Skip to content

Preview

In focus: Facing US policy risks, health care is still a viable sector

The health care sector continues to offer attractive exposure to defensive growth qualities. However, some near-term headwinds are emerging as the market digests the policy risks associated with cabinet nominees of US President-elect Donald Trump. 

While caution is advised, Templeton Global Equity Group (TGEG) aims to selectively stay invested in the sector. Our focus is on companies identified as best-in-class businesses that we believe are still undervalued or reasonably valued relative to their intrinsic worth. Examples include managed care, medical devices and diversified pharmaceuticals firms.

Investment outlook

In North America, the US market rallied into the election, and companies viewed as direct Trump beneficiaries have continued to outperform. We believe the market will now consolidate into the new year as market participants see how the president-elect’s policy implementation plays out. We will monitor this situation, but we think US equities can continue their outperformance in 2025. We believe more favorable tax policies, lighter regulation and increased small business optimism should boost the outlook for corporate profits enough to offset headwinds from higher tariffs and bond yields and reduced immigration. The US market will likely experience a rotation away from the handful of stocks most responsible for the market gains of recent years to a broader set of companies and industries. We believe the anticipated shift in market leadership will be driven by tangible earnings improvement.

In Asia Pacific, entering the last month of December, APAC equities will likely remain on uneven ground and lag their counterparts in the United States. Whereas the US market is riding on post-election optimism, investors in Asia have to grapple with a relatively uncertain macro outlook. Asia’s earnings recovery has remained on track, recording around 12% of year-on-year growth during the July-September quarter.1 However, earnings growth may have peaked this year and could decelerate in 2025 amid potentially weaker exports and slower economic growth due to the potential impact of higher US tariffs.2 Policy news may also throw up headwinds, especially for equities in mainland China and Hong Kong, as market hopes and disappointments surrounding China’s stimulus measures continue to dominate sentiment. 

In Europe, interest rates declined in 2024 at a slower rate than was expected at the end of last year, but more central banks globally are now enacting rate cuts. While there remains significant volatility in yields on long-term debt, we expect (and the market consensus expects) for rates to continue declining through 2025. Nonetheless, we believe that rates will remain much higher than was the norm in the pre-pandemic era, and for a longer period than previously expected, because of persistent and “sticky” inflation. 

Market review: November 2024

Global equities collectively rose in November 2024. In US-dollar terms, developed market equities outperformed the global benchmark MSCI All Country World Index,3 while emerging market and frontier market equities significantly underperformed it. In terms of investment style, global growth stocks outpaced global value stocks.

A significant post-election rally drove market gains. While President-elect Donald Trump’s election victory and the potential for additional tax cuts and expansionary fiscal policy bolstered US equities, investors outside the United States were more cautious as they were concerned about the president-elect’s tariff plans and their implications on global trade. On the economic front, global manufacturing activity stabilized in November after four months of contraction, while flash reports for the same month showed signs of strength in many regions.

Endnotes

  1. Source: Bloomberg. As of December 2, 2024. Based on the MSCI All Country Asia Pacific Index. The Index captures large and mid-cap representation across 5 developed market countries and 8 emerging market countries in the Asia Pacific region. Indexes are unmanaged and one cannot directly invest in them. They do not include fees, expenses or sales charges. Past performance is not an indicator of future results.
  2. Source: J.P. Morgan, “Global Markets Strategy.” As of November 27, 2024.
  3. The MSCI ACWI captures large- and mid-cap representation across 23 developed markets and 24 emerging markets countries. Indexes are unmanaged and one cannot directly invest in them. Indexes are unmanaged and one cannot directly invest in them. They do not include fees, expenses or sales charges. Past performance is not an indicator of future results.

WHAT ARE THE RISKS?

All investments involve risks, including possible loss of principal.

Equity securities are subject to price fluctuation and possible loss of principal. Small- and mid-cap stocks involve greater risks and volatility than large-cap stocks. There can be no assurance that multi-factor stock selection process will enhance performance. Exposure to such investment factors may detract from performance in some market environments, perhaps for extended periods.

Active management does not ensure gains or protect against market declines.

International investments are subject to special risks, including currency fluctuations and social, economic and political uncertainties, which could increase volatility. These risks are magnified in emerging markets. Investments in companies in a specific country or region may experience greater volatility than those that are more broadly diversified geographically. The government’s participation in the economy is still high and, therefore, investments in China will be subject to larger regulatory risk levels compared to many other countries. There are special risks associated with investments in China, Hong Kong and Taiwan, including less liquidity, expropriation, confiscatory taxation, international trade tensions, nationalization, and exchange control regulations and rapid inflation, all of which can negatively impact the fund. Investments in Taiwan could be adversely affected by its political and economic relationship with China.

Investments in fast-growing industries like the technology sector (which historically has been volatile) could result in increased price fluctuation, especially over the short term, due to the rapid pace of product change and development and changes in government regulation of companies emphasizing scientific or technological advancement or regulatory approval for new drugs and medical instruments.

Diversification does not guarantee a profit or protect against a loss.

Copyright ©2025. Franklin Templeton. All rights reserved.

This document is intended to be of general interest only. This document should not be construed as individual investment advice or offer or solicitation to buy, sell or hold any shares of fund. The information provided for any individual security mentioned is not a sufficient basis upon which to make an investment decision. Investments involves risks. Value of investments may go up as well as down and past performance is not an indicator or a guarantee of future performance. The investment returns are calculated on NAV to NAV basis, taking into account of reinvestments and capital gain or loss. The investment returns are denominated in stated currency, which may be a foreign currency other than USD and HKD (“other foreign currency”). US/HK dollar-based investors are therefore exposed to fluctuations in the US/HK dollar / other foreign currency exchange rate. Please refer to the offering documents for further details, including the risk factors.

The data, comments, opinions, estimates and other information contained herein may be subject to change without notice. There is no guarantee that an investment product will meet its objective and any forecasts expressed will be realized. Performance may also be affected by currency fluctuations. Reduced liquidity may have a negative impact on the price of the assets. Currency fluctuations may affect the value of overseas investments. Where an investment product invests in emerging markets, the risks can be greater than in developed markets. Where an investment product invests in derivative instruments, this entails specific risks that may increase the risk profile of the investment product. Where an investment product invests in a specific sector or geographical area, the returns may be more volatile than a more diversified investment product. Franklin Templeton accepts no liability whatsoever for any direct or indirect consequential loss arising from use of this document or any comment, opinion or estimate herein. This document may not be reproduced, distributed or published without prior written permission from Franklin Templeton.

Any share class with “(Hedged)” in its name will attempt to hedge the currency risk between the base currency of the Fund and the currency of the share class, although there can be no guarantee that it will be successful in doing so. In some cases, investors may be subject to additional risks.

Please contact your financial advisor if you are in doubt of any information contained herein.

For UCITS funds only: In addition, a summary of investor rights is available from here. The fund(s)/ sub-fund(s) are notified for marketing in various regions under the UCITS Directive. The fund(s)/ sub-fund(s) can terminate such notifications for any share class and/or sub-fund at any time by using the process contained in Article 93a of the UCITS Directive.

For AIFMD funds only: In addition, a summary of investor rights is available from here. The fund(s)/ sub-fund(s) are notified for marketing in various regions under the AIFMD Directive. The fund(s)/ sub-fund(s) can terminate such notifications for any share class and/or sub-fund at any time by using the process contained in Article 32a of the AIFMD Directive.

For the avoidance of doubt, if you make a decision to invest, you will be buying units/shares in the fund(s)/ sub-fund(s) and will not be investing directly in the underlying assets of the fund(s)/ sub-fund(s).

This document is issued by Franklin Templeton Investments (Asia) Limited and has not been reviewed by the Securities and Futures Commission of Hong Kong.

Unless stated otherwise, all information is as of the date stated above. Source: Franklin Templeton.

CFA® and Chartered Financial Analyst® are trademarks owned by CFA Institute.